U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Britain Courts Anthropic Amid US Defense Department Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NEW YORK, Oct. 11, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Nevada on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) securities between December 16, 2015 and September 16, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc. There is no cost or obligation to you.
According to the complaint, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Food and Drug Administration (the “FDA”) questioned whether the data from the 611 and 612 Studies were clinically significant; (2) the FDA informed defendants in December 2012 not to submit the New Drug Application based on data from the 611 and 612 Studies; and (3) accordingly, defendants’ public statements concerning the Company's business, operations and prospects were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/spectrum-pharmaceuticals-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
